LAE102是自主研发针对Act RIIA的单克隆抗体，Act RIIA是在肌肉再生和脂肪代谢中发挥重要作用的受体。在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。长城证券此前指，核心管线LAE002 和LAE001 商业化渐近，以增肌减脂药物LAE102为代表的自研管线具备良好创新前景。看好公司产品未来商业化发展。Lai Kai Medicine-B (02105) surged more than 22%, reaching a high of 17.4 Hong Kong dollars, hitting a new high for the year. As of the time of writing, it has risen by 22.48%, to 17 Hong Kong dollars, with a turnover of 0.178 billion Hong Kong dollars.
According to the Wisdom Finance APP, Lai Kai Medicine-B (02105) surged more than 22%, reaching a high of 17.4 Hong Kong dollars, hitting a new high for the year. As of the time of writing, it has risen by 22.48%, to 17 Hong Kong dollars, with a turnover of 0.178 billion Hong Kong dollars.
On the news front, Lai Kai Medicine recently announced that the group has signed a clinical cooperation agreement with Eli Lilly and Co, aimed at supporting and accelerating the global clinical development of LAE102 for the treatment of obesity. Eli Lilly will be responsible for conducting a Phase I study in the USA and bearing the related costs. The group retains the global rights to LAE102.
LAE102 is a monoclonal antibody developed independently targeting Act RIIA, a receptor that plays an important role in muscle regeneration and fat metabolism. In preclinical models, LAE102 has shown effects of increasing muscle and reducing fat. China Great Wall Securities previously pointed out that the core pipeline, including LAE002 and LAE001, is approaching commercialization, and the self-developed pipeline represented by the muscle-building and fat-reducing drug LAE102 has good prospects for innovation. Bullish on the future commercial development of the company's products.
